Early this morning in an interview with CNBC's "Squawk Box", Warren Buffet revealed his 54-year strategy is unchanged by the situation in Washington, noting the ongoing crisis in Washington over spending and the debt limit is no reason to avoid buying. Considering the advice of one of the most successful players in the market today, this week may be an excellent opportunity for many readers to get involved in NNRX.
Continuing its string of developments, NNRX announced this morning it has secured a purchase order from a health food supplement distribution company with over 25,000 distributors. In addition to the initial purchase order, the client has also requested that Nutranomics (NNRX) develop up to six new products for their exclusive distribution. Possibly one of the most important revelations was the fact that these products are already registered with the Asian country's FDA equivalent, the BFAD.
"Not only will this client be adding six new Nutranomics products to their distribution network, but the really good news for their more than 25,000 distributors is that the new products are already registered with the Philippines' equivalent of the FDA, the BFAD," commented Dr. Tracy K. Gibbs. "We expect that the new products will be available across their distribution network shortly."
Yesterday NNRX closed at $0.56, setting the stage perfectly for new highs. This demonstrates that NNRX is establishing STRONG SUPPORT in the 50's, following gains of 16.24% Monday and 20.44% on Friday. This is confirmation of sustainability and support in continuing the trend back toward $1.00+ levels.
☝ Market Knowledge: No company goes straight up. All successful companies follow an upward trend line, establishing higher highs and higher lows on the way up. It is healthy for companies to see a pullback and establish new higher support before continuing upward to new highs.
Remember, this company has already seen $1.00+ levels very recently and with a low float, growing revenue and upcoming human clinical trial results – NNRX appears to be a clear candidate to see high percentage gains in the coming weeks.
It is our strong belief, based on facts outlined below, that Nutranomics (NNRX) is our most discounted selection to date. In our eyes, when compared to our past selections during coverage, NNRX is quite simply the best company value to market valuation ratio. As a result, we expect to see a recovery upward to original levels above $1.00.
☝ The Facts: Read our reasoning as to why we believe NNRX is on the verge of a recovery run. For those looking to participate in what could be a substantial positive correction in NNRX, 50 - 60 cents could be an ideal entry. If NNRX recovers to previous levels, a 55 cent entry could turn $10,000 into $25,800 or more in a very short period of time.
Early October, NNRX announced Human Clinical Study Results for its Glucozyme(TM) product. Glucozyme(TM) aids in the processing of sugars to maintain proper glucose and insulin levels in patients with diabetes and pre-diabetes. Following the successful release of results from the clinical studies, Glucozyme will be one step closer to helping patients manage their glucose levels more effectively and potentially prevent diabetes from impacting their lives dramatically. The results are expected from the clinical studies within the next 2-3 weeks.
For those value seekers who look to fundamentals for strategy confirmation, NNRX
is an exception to the traditional risk associated within early stage clinical trial companies. Rather than wait on a "homerun" clinical study, NNRX
has worked diligently to establish revenue and distribution of a diverse range of products. NNRX has Consistently Reported Over +2.8M in Yearly Revenue
, disclosed in its recent regulatory filings
. As more participants realize the solid revenue situation, combined with the upside of upcoming clinical trial results, NNRX
could gain a large base of loyal followers. IMPORTANT UPDATE
: On Friday Oct 11, NNRX
announced 44% YoY sales growth
in Japan for its recent quarter when compared to the same 3 month period last year.
Two of the most important factors to pay attention to when evaluating a particular company, are share count and market capitalization. These two metrics are often naively overlooked.
The first factor represents "Supply". The shorter the supply, the greater the potential for upward momentum. If a catalyst event strikes, as is often the case in companies engaged in clinical trials, those with the smallest floats see the sharpest spikes. NNRX has Under 47M Outstanding with over 40% of that locked up with management.
The second factor represents "Valuation". This is a comparison of current price versus value offered by the company. At its current levels, NNRX sits at A Market Value of Less Than 50M. This is for a company reporting in excess of +2.8M in yearly revenue and human clinical results upcoming for a diabetes product. Although valuation varies depending on individual criterion and goals, we believe that 50M is far below the fair value placed by the average market participant. As more and more people begin to do the math and discover NNRX's current valuation, prices could quickly correct upward.
Given the facts above, NNRX is the type of candidate we believe could recover very quickly to previous levels above $1.00 once the daily price action tips in favor of upward momentum. For those with much longer term outlooks, take a look at NUAN going forward (worthy of mention due to the addition of Icahn's two experienced players to its board) – although remember this is a longer term outlook than the immediate upside we see in NNRX.
It's Your Turn
Remember – all of the above information is just that, information. It represents our opinion only. Please use this as a starting point for your own due diligence and read our disclaimer and disclosures. Come to your own conclusions about NNRX and where you believe it will go. For us, we believe the facts will speak for themselves.
Take Reasonable Action
Please keep in mind, the ideas discussed carry a high degree of risk and information is intended for a professional audience. If you are not a professional, consult with one. We cannot provide personal advice. We are biased, compensated and not required to be registered. For further detail on how this may affect your decision making process, carefully read our disclaimer and disclosures.
||Nugget Enterprises LLC